Skin Cancer Diagnostics Market Size & Growth | Forecast 2028
The global skin cancer diagnostics market generated US$ 3,364.46 million in 2021 and is projected to account for US$ 5,480.45 million by 2028, expanding at a CAGR of 7.2% during 2021–2028.
The increasing incidences of skin cancer and launch of new products are the primary aspects buoying the market growth, while the barriers to early skin cancer diagnostics in low and middle-income countries curtail the expansion of global skin cancer diagnostics market
Carcinogenic condition of the skin arises due to abnormal growth of skin cells, generally occuring in the areas exposed to the sun. Ultraviolet (UV) radiation, a leading cause of skin cancer, alters the genetic composition (DNA) of cells. Melanoma and non-melanoma are the two main categories of skin cancer. Several imaging solutions such as CT scans, MRIs, PET scans, bone scans, and chest X-rays are used to diagnose the disease. Besides, the diagnostic therapies include chemotherapy, targeted therapy, immunotherapy, radiotherapy, freezing treatment, and scraping therapy to help cure the dermal condition.
Regionally, North America held the major share of the global skin cancer diagnostics market and is likely to retain its dominance throughout the forecast period. Asia Pacific, the most lucrative market, is speculated to spur at the fastest pace due to increasing number of clinical trials and rising investments to develop new dermal therapies. Prominent skin cancer diagnostics market players have been into organic and inorganic developments. The former includes product launches and approvals while the latter constitutes collaboration, acquisitions, and partnerships. To put in figures, organic developments hold 74% of the strategic growth, whereas inorganic developmental contribution accounts for 26% of the business expansion. Such growth strategies have helped companies enhance their market value and affirm the position.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Global Skin Cancer Diagnostics Market: Strategic Insights
Market Size Value in US$ 3,364.46 Million in 2021 Market Size Value by US$ 5,480.45 Million by 2028 Growth rate CAGR of 7.2% from 2021 to 2028 Forecast Period 2021-2028 Base Year 2021
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Global Skin Cancer Diagnostics Market: Strategic Insights
| Market Size Value in | US$ 3,364.46 Million in 2021 |
| Market Size Value by | US$ 5,480.45 Million by 2028 |
| Growth rate | CAGR of 7.2% from 2021 to 2028 |
| Forecast Period | 2021-2028 |
| Base Year | 2021 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
COVID-19 Impact
Delays and Interruptions in the Non-Urgent Dermal Surgeries Ceased the Global Skin Cancer Diagnostics Market
The global COVID-19 pandemic disrupted the skin cancer diagnostics market and halted business operations. In North America, the non-urgent medical services stood interrupted. Lockdown in the region during 2020 to mid-2021 led to delayed clinical visits. The diagnosis of melanoma and other skin cancers took longer than usual. Hospitals encountered drastic reduction in skin biopsies. With 15% drop in skin biopsy number, a huge backlog remained uncleared during the pandemic. Treatment and management post diagnosis were delayed leading to certain death instances due to dermal cancer. In 2020, melanoma alone reported around 5.6% of all cancer cases in the US causing maximum fatalities. Overall, the pandemic had a profound impact on the routine management of skin cancer services in the US.
In Europe, the elected surgeries including skin cancer excisions were postponed. The healthcare routine changed radically with severe impact on surgical practices. Carcinogenic treatments were hampered with detection and diagnosis being missed and therapies came to standstill. Postponing visits led to complex health implications. Although, skin biopsies resumed post pandemic, a large pile of un-intervened cases remained for almost half a year. Prioritizing COVID infected patients and desisting other medical services had put the healthcare industry in Asia Pacific in crucial position. Medical resources were rationalized to manage the influx of COVID-19 cases. This wreaked havoc in the routine care system of cancer patients. the delays and disruptions in timely healthcare access worsened conditions coercing patients to opt for expensive advanced carcinogenic treatment. The regular cancer screening practices across the region were halted. Medical systems in the region started recognizing the fickle and deadly nature of cancer with its intersection with other widespread health problems.
Future Trends
AI Assisted Skin Cancer Diagnostics
Advanced dermatoscopes aid in better visualization of skin cancer with diagnostic sensitivity improved by 10–30%. Similarly, the applications of artificial intelligence (AI) technology branched into the early-stage skin cancer detection. In February 2022, researchers at Fraunhofer Center for Assistive Information and Communication Solutions (AICOS) introduced Derm.AI software offering primary assessment of skin lesions that look potentially harmful. The software is likely to assist dermatologists to analyze the cases and risk of skin cancer. In January 2017, a group of researchers at Stanford University, developed an AI algorithm for skin cancer diagnosis. They created a database of over 130,000 skin disease images and their algorithm visualizes potential cancer from the very first test. Veriskin Inc. introduced TruScore, a non-invasive, low-cost, and hand-held device supported by AI for skin cancer diagnostics and screening.
Drivers
Increasing Incidences of Skin Cancer
According to the WHO, over 1.20 million skin cancer cases were reported in 2020. Skin cancer is by far the most common of all cancer types. Although Melanoma accounts for around 1% of total skin cancer cases, it causes maximum death instances. The rate of melanoma occurrence rapidly increased in the past few decades, varying with the age. Increased exposure to UV rays leads to genetic mutations causing prolonged skin cancer condition. According to the American Cancer Society’s statistics of 2022, around 7,650 people are likely to lose it to melanoma with approximately 5080 men and 2570 women. As per the GLOBOCAN 2020, over 19.3 million cancer cases, excluding 18.1 million nonmelanoma skin cancer cases were registered across the world. Several countries have adopted nationwide programs for cancer awareness and early diagnosis, thereby driving the growth of global skin cancer diagnostics market.
Launch of New Skin Cancer Diagnostics Products
Early detection and timely diagnosis of skin cancer grants the lease of life to cancer patients. in response to this, various companies emphasize offering advanced products for the skin cancer quicker diagnosis. 3Derm Systems, Inc. developed 3DermSpot, an AI-based algorithm that autonomously detects melanoma, squamous cell carcinoma, and basal cell carcinoma using standard skin images. DermaSensor Inc. introduced DermaSensor device as an objective tool to assess lesions suggestive of skin cancer. The device provides feedback on cellular substructures that are invisible to the naked eye, even after inspected by dermatoscopy. In May 2021, SciBase Holding AB launched its non-melanoma skin cancer (NMSC) clinical application and MDR certification process. Such innovations by major market players are certain to accelerate the growth of global skin cancer diagnostics market.
Restraints
Barriers to Early Skin Cancer Diagnostics Market in Low and Middle-Income Countries
The poor literacy regarding health, stigma around cancer, limited access to primary care, inaccurate clinical assessments, delay in clinical diagnostics, inaccessibility of testing, and lack of people’s follow up are the legit factors hindering the early diagnosis of cancer in low and middle-income economies. An improper healthcare management often diagnose the cancer in last or intermediate stage, eventually leading to the increased fatality rates. The lack of awareness surged cancer incidences and mortality among children in average economy countries. However, the healthcare providers there lack the resources critical to upgrade medical infrastructure and service quality. High diagnostic and imaging equipment costs, low reimbursement rates, and budgetary constraints limit the cancer diagnosis leading to unspecific and insensitive diagnostic results. These challenges in low-income regions restrict the growth of global skin cancer diagnostics market.
Market Segmentation
By Type
Rising Incidences of Types of Non-Melanoma Skin Cancer Surged the Segmental Growth
The global skin cancer diagnostics market, by type, is split into melanoma and non-melanoma. The latter dominated the market in 2021 with the largest revenue share and is anticipated to spur at the highest CAGR during the forecast period. The segmental growth is accustomed to the rising instances of basal cell and squamous cell carcinoma and the awareness campaigns about non-melanoma skin cancer. Though curable through surgery and rarely lethal, the surgical treatment of nonmelanoma cancer is painful and disfiguring. The incidences are difficult to determine due to inefficient reliable registration. Countries located in the decreasing latitudinal region having higher levels of UV radiations have reported more instances of nonmelanoma cancer. The Skin Cancer Foundation stated that over 5,400 patients succumb to non-melanoma cancer every month globally.
The melanoma segment was the second-largest occupant of the global skin cancer diagnostics market in 2021. As per the WHO data published in October 2017, approximately 132,000 melanoma skin cancer cases are registered worldwide every year. In the US, the instances increased by an average of 4%. According to the GLOBOCAN 2020, the number of new melanoma cases in 2020 were close to 324,635. Though malignant melanoma skin cancer is less prevalent than non-melanoma one, it still remains a major cause of fatality.
By Screening Type
Numerous Benefits of Biopsy Procedure Upheld the Segment’s Dominance
Based on screening type, the global skin cancer diagnostics market is segmented into skin biopsy, blood tests, dermatoscopy, imaging tests, and lymph node biopsy. The skin biopsy segment occupied the largest market share in 2021 and is likely to register the highest CAGR over the forecast period. The skin biopsy procedure requires a small part of the skin to be cut and removed for the test. It detects the skin cancer, infection, or other skin conditions. Skin samples are collected and assessed by different types of biopsies such as punch, excisional, incisional, and shave biopsy. Particularly, in case of non-melanoma, biopsy is often the only test to diagnose the stage or extension of the cancer.
The dermatoscopy segment follows the skin biopsy to encompass the global skin cancer diagnostics market in 2021. It is one of the fastest growing segments. It sensitizes detecting the skin cancer, reduces the number of benign lesions biopsied, and enables the diagnosis of thinner melanomas. Owing to these benefits, dermatoscopy is widely used as primary screening test for skin cancer. It has been a cost-effective procedure, leading to the decreased number of excised benign lesions. Dermatoscopes are light-weight, battery-operated, and handy with convenient attachments to record though smartphones.
Regional Insights
Geographically, the global skin cancer diagnostics market is segmented into North America, Europe, Asia Pacific (APAC), South & Central America (SCAM), and Middle East & Africa (MEA).
North America held the largest market share in 2021 and is forecasted to retain its dominance till 2028. The region’s highest market occupancy is attributed to the increasing incidences of skin cancer, rising awareness, and increasing product launches. The US market is thriving on skin cancer incidences, increasing government support, and advanced products for detection in the Skin Cancer Diagnostics market. research states that non-melanoma skin cancers such as BCC and SCC affects over 3 million American citizens every year. The Skin Cancer Foundation revealed that at least 1 in 5 Americans will develop skin cancer by the age of 70. In Canada, melanoma has been highly prevalent and equally fatal for the cancer patients. Morbidity due to skin cancer is becoming usual across the country. According to the Canadian Skin Cancer Foundation, every year more than 80,000 skin cancer cases are registered of which around 5,000 cases report melanoma skin cancer. The number of skin cancer cases across the country is more than the number of breast, prostate, lung, and colon cancer cases put together.
Asia Pacific skin cancer diagnostics market is projected to expand with the highest CAGR over the forecast period. The regional market growth is ascribed to rapidly growing geriatric population, improving healthcare infrastructure, growing per capita income, and developments by major players. Besides, the increasing number of clinical trials, public and private investment in the therapeutic development, increasing expenditure on R&D activities, advanced clinical technologies, and innovative medical diagnostic devices are among the prominent aspects propelling the regional Skin Cancer Diagnostics market growth over the projection period. In China, skin cancer has been a significant public health problem. Country’s rapidly aging population continues to put a financial strain on healthcare system. Exposure to ultraviolet B radiation and higher levels of arsenic in drinking water has been linked to skin cancer in India. According to the Indian Council of Medical Research (ICMR), northern part of India has the highest melanoma incidences.
Skin Cancer Diagnostics Market Report Scope
Key Market Players:
- SkylineDx BV (Netherlands)
- AMLo Biosciences Limited (UK)
- NeraCare GmbH (Germany)
- DermLite LLC (USA)
- bioMerieux SA (France)
- Veriskin Inc (US)
- Castle Biosciences, Inc. (US)
- DermTech Inc (US)
- HOFFMANN-LA ROCHE LTD (Switzerland)
- Michelson Diagnostics Ltd (UK)
Key Developments:
December 2021:
SkyineDx entered into a 3-year strategic partnership with Life Sciences’ institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics.July 2020:
Veriskin received US FDA breakthrough device designation for its TruScore device.April 2021:
Castle Biosciences, Inc. signed a definitive agreement to acquire entire equity of Myriad myPath, LLC (Myriad myPath Laboratory) from Myriad Genetics for US$ 32.5 million.
Report Coverage
The global skin cancer diagnostics market research report provides detailed insights into the market in terms of size, share, trends, and forecasts. It delivers crisp and precise know-how of drivers, restraints, opportunities, segments, and industrial landscape. The COVID-19 impact analysis is discussed with the consequences followed in global and regional markets. A list of key market players with their respective developments in recent years has been reserved as a special mention.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Screening Type
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Skin cancer diagnostics market is segmented by geography into North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. North America held the largest market share for skin cancer diagnostics. The United States held the largest market in North America for skin cancer diagnostics, and the market is expected to grow due to the increasing incidences of skin cancer, growing awareness about skin cancer, increasing government support for preventing and controlling skin cancer incidences, and increasing product launches As per the Skin Cancer Foundation, the annual cost of treating skin cancer in the country is estimated to be US$ 8.1 billion. Nearly US$ 4.8 billion is spent on non-melanoma skin cancer treatment and ~US$ 3.3 billion is spent on treating melanoma skin cancer. However, Asia Pacific registered as the fastest-growing region in the global skin cancer diagnostics market. The growth of the market is expected to grow due to the improving healthcare infrastructure, growing per capita income, and the increasing focus of key market players on this region.
The skin cancer diagnostics market majorly consists of the players such SkylineDx BV; AMLo Biosciences Limited; NeraCare GmbH; DermLite LLC; bioMerieux SA; Veriskin Inc.; Castle Biosciences, Inc.; DermTech Inc.; F. Hoffmann-La Roche Ltd., and Michelson Diagnostics Ltd. among others.
Skin cancer is the most common form of cancer. There are two main categories of skin cancer such as melanoma and non-melanoma. Various imaging solutions such as CT scans, MRIs, PET scans, bone scans, and chest X-rays are used to diagnose skin cancer. The skin cancer diagnostics market also includes various diagnostics and therapies related to skin cancer, such as chemotherapy, targeted therapy, immunotherapy, radiotherapy, freezing treatment, and scraping therapy that helps cure skin cancer.
Key factors that are driving the growth of the skin cancer diagnostics market over years are the increasing incidence of skin cancer and launch of new products.
The non-melanoma segment dominated the skin cancer diagnostics market and held the largest market share of 65.13% in 2021.
The skin biopsy segment dominated the skin cancer diagnostics market and held the largest market share of 52.31% in 2021.
1. Introduction
1.1 Scope of the Study.
1.2 The Insight Partners Research Report Guidance.
1.3 Market Segmentation.
1.3.1 Global Skin Cancer Diagnostics Market – By Type.
1.3.2 Global Skin Cancer Diagnostics Market – By Screening Type.
1.3.3 Global Skin Cancer Diagnostics Market – By Geography.
2. Key Takeaways
3. Research Methodology
3.1 Coverage.
3.2 Secondary Research.
3.3 Primary Research.
4. Global Skin Cancer Diagnostics Market – Market Landscape
4.1 Overview.
4.2 PEST Analysis.
4.2.1 North America– PEST Analysis.
4.2.2 Europe– PEST Analysis.
4.2.3 Asia Pacific– PEST Analysis.
4.2.4 Middle East and Africa– PEST Analysis.
4.2.5 South and Central America– PEST Analysis.
4.3 Expert Opinion.
5. Skin Cancer Diagnostics Market – Key Market Dynamics
5.1 Market Drivers.
5.1.1 Increasing Incidence of Skin Cancer.
5.1.2 Launch of New Products.
5.2 Market Restraints.
5.2.1 Barriers to Early Skin Cancer Diagnostics in Low and Middle-Income Countries.
5.3 Market Opportunities.
5.3.1 Government Support for Early Skin Cancer Diagnosis.
5.4 Future Trends.
5.4.1 Skin Cancer Diagnostics Through AI
5.5 Impact Analysis.
6. Skin Cancer Diagnostics Market – Global Analysis
6.1 Global Skin Cancer Diagnostics Market Revenue Forecast and Analysis.
6.2 Global Skin Cancer Diagnostics Market Revenue Forecast and Analysis.
6.3 Market Positioning of Key Players.
7. Skin Cancer Diagnostics Market Analysis – By Type
7.1 Overview.
7.2 Skin Cancer Diagnostics Market Revenue Share, by Type (2021 and 2028)
7.3 Melanoma.
7.3.1 Overview..
7.3.2 Melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Non-melanoma.
7.4.1 Overview..
7.4.2 Non-melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8. Skin Cancer Diagnostics Market – By Screening Type
8.1 Overview.
8.2 Skin Cancer Diagnostics Market, by Screening Type, 2021 and 2028 (%)
8.3 Blood Tests.
8.3.1 Overview..
8.3.2 Blood Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Dermatoscopy.
8.4.1 Overview..
8.4.2 Dermatoscopy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Imaging Tests.
8.5.1 Overview..
8.5.2 Imaging Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Lymph Node Biopsy.
8.6.1 Overview..
8.6.2 Lymph Node Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Skin Biopsy.
8.7.1 Overview..
8.7.2 Skin Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9. Skin Cancer Diagnostics Market – Regional Analysis
9.1 North America: Skin Cancer Diagnostics Market
9.1.1 Overview..
9.1.2 North America: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.3 North America: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.4 North America: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ Million)
9.1.5 North America: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
9.1.5.1 US: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.1.1 US: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.1.2 US: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.5.1.3 US: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.1.5.2 Canada: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.2.1 Canada: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.2.2 Canada: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.5.2.3 Canada: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.1.5.3 Mexico: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.3.1 Mexico: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.3.2 Mexico: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.5.3.3 Mexico: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.2 Europe: Skin Cancer Diagnostics Market
9.2.1 Overview..
9.2.2 Europe: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.3 Europe: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.4 Europe: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5 Europe: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
9.2.5.1 Germany: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.1 Overview..
9.2.5.1.2 Germany: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.3 Germany: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.1.4 Germany: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.2 United Kingdom: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.1 Overview..
9.2.5.2.2 United Kingdom: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.3 United Kingdom: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.2.4 United Kingdom: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.3 France: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.1 Overview..
9.2.5.3.2 France: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.3 France: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.3.4 France: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.4 Italy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.1 Overview..
9.2.5.4.2 Italy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.3 Italy: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.4.4 Italy: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.5 Spain: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.1 Overview..
9.2.5.5.2 Spain: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.3 Spain: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.5.4 Spain: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.6 Rest of Europe: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.1 Overview..
9.2.5.6.2 Rest of Europe: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.3 Rest of Europe: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.6.4 Rest of Europe: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.3 Asia Pacific Skin Cancer Diagnostics Market Revenue and Forecasts To 2028.
9.3.1 Overview..
9.3.2 Asia-Pacific: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.3 Asia-Pacific: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.3.4 Asia-Pacific: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.3.5 Asia-Pacific: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
9.3.5.1 China: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.1.1 Overview..
9.3.5.1.2 China: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ MILLION)
9.3.5.1.3 China: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.3.5.1.4 China: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.3.5.2 Japan: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ MILLION)
9.3.5.2.1 Overview..
9.3.5.2.2 Japan: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.2.3 Japan: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.3.5.2.4 Japan: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.3.5.3 India: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.3.1 Overview..
9.3.5.3.2 India: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.3.3 India: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.3.5.3.4 India: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.3.5.4 South Korea: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.4.1 Overview..
9.3.5.4.2 South Korea: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.4.3 South Korea: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.3.5.4.4 South Korea: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.3.5.5 Australia: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.5.1 Overview..
9.3.5.5.2 Australia: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.5.3 Australia: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.3.5.5.4 Australia: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.3.5.6 Rest of Asia-Pacific: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.1 Overview..
9.3.5.6.2 Rest of Asia-Pacific: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.3 Rest of Asia-Pacific: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.3.5.6.4 Rest of Asia-Pacific: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.4 Middle East and Africa: Skin Cancer Diagnostics Market
9.4.1 Overview..
9.4.2 Middle East and Africa: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.4.3 Middle East and Africa: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.4.4 Middle East and Africa: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ Million)
9.4.5 Middle East and Africa: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
9.4.5.1 UAE: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.4.5.1.1 UAE: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.4.5.1.2 UAE: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.4.5.1.3 UAE: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.4.5.2 Saudi Arabia: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.4.5.2.1 Saudi Arabia: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.4.5.2.2 Saudi Arabia: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.4.5.2.3 Saudi Arabia: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.4.5.3 South Africa: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.4.5.3.1 South Africa: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.4.5.3.2 South Africa: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.4.5.3.3 South Africa: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.4.5.4 Rest of Middle East and Africa: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.4.5.4.1 Rest of Middle East and Africa: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.4.5.4.2 Rest of Middle East and Africa: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.4.5.4.3 Rest of Middle East and Africa: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.5 South and Central America: Skin Cancer Diagnostics Market
9.5.1 Overview..
9.5.2 South and Central America: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.5.3 South and Central America: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.5.4 South and Central America: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ Million)
9.5.5 South and Central America: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
9.5.5.1 Brazil: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.5.5.1.1 Brazil: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.5.5.1.2 Brazil: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.5.5.1.3 Brazil: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.5.5.2 Argentina: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.5.5.2.1 Argentina: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.5.5.2.2 Argentina: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.5.5.2.3 Argentina: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.5.5.3 Rest of South and Central America: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.5.5.3.1 Rest of South and Central America: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.5.5.3.2 Rest of South and Central America: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.5.5.3.3 Rest of South and Central America: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
10. Impact of COVID-19 Pandemic on Global Skin Cancer Diagnostics Market
10.1 North America: Impact Assessment of COVID-19 Pandemic.
10.2 Europe: Impact Assessment of COVID-19 Pandemic.
10.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic.
10.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic.
10.5 South and Central America: Impact Assessment of COVID-19 Pandemic.
11. Skin Cancer Diagnostic Market–Industry Landscape
11.1 Overview.
11.2 Growth Strategies in the Skin Cancer Diagnostic Market (%)
11.3 Organic Developments.
11.3.1 Overview..
11.4 Inorganic Developments.
11.4.1 Overview..
12. Company Profiles
12.1 SkylineDx BV.
12.1.1 Key Facts.
12.1.2 Business Description.
12.1.3 Products and Services.
12.1.4 SWOT Analysis.
12.1.5 Key Developments.
12.2 AMLo Biosciences Limited.
12.2.1 Key Facts.
12.2.2 Business Description.
12.2.3 Products and Services.
12.2.4 SWOT Analysis.
12.2.5 Key Developments.
12.3 NeraCare GmbH.
12.3.1 Key Facts.
12.3.2 Business Description.
12.3.3 Products and Services.
12.3.4 SWOT Analysis.
12.3.5 Key Developments.
12.4 DermLite LLC.
12.4.1 Key Facts.
12.4.2 Business Description.
12.4.3 Products and Services.
12.4.4 Financial Overview..
12.4.5 SWOT Analysis.
12.4.6 Key Developments.
12.5 bioMerieux SA.
12.5.1 Key Facts.
12.5.2 Business Description.
12.5.3 Products and Services.
12.5.4 Financial Overview..
12.5.5 SWOT Analysis.
12.5.6 Key Developments.
12.6 Veriskin Inc.
12.6.1 Key Facts.
12.6.2 Business Description.
12.6.3 Products and Services.
12.6.4 Financial Overview..
12.6.5 SWOT Analysis.
12.6.6 Key Developments.
12.7 Castle Biosciences, Inc.
12.7.1 Key Facts.
12.7.2 Business Description.
12.7.3 Products and Services.
12.7.4 Financial Overview..
12.7.5 SWOT Analysis.
12.7.6 Key Developments.
12.8 DermTech Inc.
12.8.1 Key Facts.
12.8.2 Business Description.
12.8.3 Products and Services.
12.8.4 Financial Overview..
12.8.5 SWOT Analysis.
12.8.6 Key Developments.
12.9 HOFFMANN-LA ROCHE LTD.
12.9.1 Key Facts.
12.9.2 Business Description.
12.9.3 Products and Services.
12.9.4 Financial Overview..
12.9.5 SWOT Analysis.
12.10 Michelson Diagnostics Ltd.
12.10.1 Key Facts.
12.10.2 Business Description.
12.10.3 Products and Services.
12.10.4 Financial Overview..
12.10.5 SWOT Analysis.
12.10.6 Key Developments.
13. Appendix
13.1 About The Insight Partners.
13.2 Glossary of Terms.
LIST OF TABLES
Table 1. North America: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 2. North America: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. US: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 4. US: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 5. Canada: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 6. Canada: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 7. Mexico: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 8. Mexico: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 9. Europe Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 10. Europe Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 11. Germany Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. Germany Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 13. United Kingdom Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. United Kingdom Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 15. France Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 16. France Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 17. Italy Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. Italy Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 19. Spain Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 20. Spain Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of Europe Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Europe Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 23. Asia-Pacific Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 24. Asia-Pacific Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 25. China Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 26. China Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 27. Japan Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 28. Japan Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 29. India Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 30. India Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 31. South Korea Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 32. South Korea Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 33. Australia Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 34. Australia Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 35. Rest of Asia-Pacific Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 36. Rest of Asia-Pacific Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 37. Middle East and Africa: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 38. Middle East and Africa: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ Million)
Table 39. UAE: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 40. UAE: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 41. Saudi Arabia: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 42. Saudi Arabia: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 43. South Africa: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 44. South Africa: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 45. Rest of Middle East and Africa: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 46. Rest of Middle East and Africa: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 47. South and Central America: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 48. South and Central America: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ Million)
Table 49. Brazil: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 50. Brazil: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 51. Argentina: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 52. Argentina: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 53. Rest of South and Central America: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 54. Rest of South and Central America: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 55. Organic Developments in the Skin Cancer Diagnostic Market
Table 56. Inorganic Developments in the Skin Cancer Diagnostics Market
Table 57. Glossary of Terms, Skin Cancer Diagnostics Market
Table 58. Acronym..
LIST OF FIGURES
Figure 1. Skin Cancer Diagnostics Market Segmentation.
Figure 2. Skin Cancer Diagnostics Market, By Region.
Figure 3. Global Skin Cancer Diagnostics Market Overview.
Figure 4. Non-Melanoma Segment Held Largest Share of Type Segment in Skin Cancer Diagnostics Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period.
Figure 6. Skin Cancer Diagnostics Market, by Geography (US$ Million)
Figure 7. Global Skin Cancer Diagnostics Market- Leading Country Markets (US$ Million)
Figure 8. Global Skin Cancer Diagnostics Market, Industry Landscape.
Figure 9. North America PEST Analysis.
Figure 10. Europe PEST Analysis.
Figure 11. Asia Pacific PEST Analysis.
Figure 12. Middle East and Africa PEST Analysis.
Figure 13. South and Central America PEST Analysis.
Figure 14. Skin Cancer Diagnostics Market Impact Analysis of Driver and Restraints.
Figure 15. Global Skin Cancer Diagnostics Market– Revenue Forecast and Analysis – 2020- 2028.
Figure 16. Global Skin Cancer Diagnostics Market– Revenue Forecast and Analysis – 2021 - 2028.
Figure 17. Market Positioning of Key Players in Global Skin Cancer Diagnostics Market
Figure 18. Skin Cancer Diagnostics Market Revenue Share, by Type (2021 and 2028)
Figure 19. Melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Non-melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Skin Cancer Diagnostics Market, by Screening Type, 2021 and 2028 (%)
Figure 22. Blood Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Dermatoscopy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Imaging Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Lymph Node Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Skin Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. North America: Skin Cancer Diagnostics Market, by Key Country – Revenue (2021) (US$ ‘Million)
Figure 28. North America: Skin Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ ‘Million)
Figure 29. North America: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 30. US: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 31. Canada: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 32. Mexico: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 33. Europe: Skin Cancer Diagnostics Market, by Key Country – Revenue (2021) (US$ Million)
Figure 34. Europe Skin Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
Figure 35. Europe: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 36. Germany: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. United Kingdom: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. France: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Italy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Spain: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Rest of Europe: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Asia-Pacific: Skin Cancer Diagnostics Market, by Key Country – Revenue (2021) (US$ Million)
Figure 43. Asia-Pacific Skin Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
Figure 44. Asia-Pacific: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 45. China: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ MILLION)
Figure 46. Japan: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 47. India: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 48. South Korea: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 49. Australia: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 50. Rest of Asia-Pacific: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 51. Middle East and Africa: Skin Cancer Diagnostics Market, by Key Country – Revenue (2021) (US$ ‘Million)
Figure 52. Middle East and Africa: Skin Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ ‘Million)
Figure 53. Middle East and Africa: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 54. UAE: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 55. Saudi Arabia: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 56. South Africa: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 57. Rest of Middle East and Africa: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 58. South and Central America: Skin Cancer Diagnostics Market, by Key Country – Revenue (2021) (US$ ‘Million)
Figure 59. South and Central America: Skin Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ ‘Million)
Figure 60. South and Central America: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 61. Brazil: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 62. Argentina: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 63. Rest of South and Central America: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 64. Impact Of COVID-19 Pandemic in North American Country Markets.
Figure 65. Impact of COVID-19 Pandemic in European Country Markets.
Figure 66. Impact of COVID-19 Pandemic in Asia Pacific Countries.
Figure 67. Impact Of COVID-19 Pandemic in Middle East & Africa Country Markets.
Figure 68. Impact of COVID-19 Pandemic in South and Central American Countries.
Figure 69. Growth Strategies in the Skin Cancer Diagnostic Market (%) 1
The List of Companies - Skin Cancer Diagnostics Market
- SkylineDx BV
- AMLo Biosciences Limited
- NeraCare GmbH
- DermLite LLC
- bioMerieux SA
- Veriskin Inc.
- Castle Biosciences, Inc.
- DermTech Inc.
- HOFFMANN-LA ROCHE LTD.
- Michelson Diagnostics Ltd
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For